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Testing Needed for Acesulfame
Potassium, an Artificial
Sweetener
In their article “First Experimental
Demonstration of the Multipotential
Carcinogenic Effects of Aspartame Adminis-
tered in the Feed of Sprague-Dawley Rats,”
Soffritti et al. (2006) present interesting
data on the carcinogenic effects of long-
term exposure to aspartame, an artificial
sweetener, in experimental animals (rats). 
Recently, aspartame was supplanted as
the leading artificial sweetener by sucralose,
marketed in the United States under the
trade name Splenda (McNeil Nutritionals,
LLC, Ft. Washington, PA). As of 2005,
Splenda was reported to have > 50% of the
market for artificial sweeteners, while aspar-
tame [Equal (Merisant Company, Chicago,
IL); NutraSweet (NutraSweet Property
Holdings Inc., Chicago, IL)] had < 20%
(Associated Press 2005). Splenda is typically
used in sweetener blends, most frequently
with acesulfame potassium (CAS RN
55589-62-3) (Sunett; marketed in the
United States by Nutrinova, Somerset, NJ). 
The Food and Drug Administration’s
(FDA) multiple approvals of food additive
petitions (FAPs) for acesulfame began in
1988 (FDA 1988), and culminated in
1998 with approval of the use of acesul-
fame in soft drinks (FDA 1998), histori-
cally the largest single use of artificial
sweeteners. All of the FDA’s approvals of
FAPs for acesulfame were grounded on
the conclusion that safety studies, includ-
ing long-term animal tests of acesulfame
carried out for Hoechst, the manufacturer
of the chemical, in the Netherlands in the
1970s, were adequate and the test results
indicated safety. 
The 1970s tests of acesulfame—two
tests carried out in rats and one in mice—
are inadequate to establish lack of potential
carcinogenicity. Here are a few reasons why
the tests are inadequate [Center for Science
in the Public Interest (CSPI) 1996]:
• Subchronic tests were not conducted for
the rats and mice used in the tests on
which the FAPs rested
• It is likely the minimum toxic dose/maxi-
mum tolerated dose (MTD) was not
achieved in the rat and mouse studies
• Randomization of test groups was not
carried out properly
• Mice were held on test for only 80 weeks,
rather than the 104 weeks characteristic of
National Toxicology Program (NTP)
bioassays
• Animal husbandry and monitoring of ani-
mals on test were evidently poor, as indi-
cated by high disease rates in the animals
and extensive autolysis of tissues.
Even with the flaws in design and exe-
cution of the Hoechst tests, results indi-
cated an association between treatment with
acesulfame and carcinogenesis (CSPI 1996). 
Working-level staff members at the
FDA identified deficiencies in the acesul-
fame tests in the 1980s (McLaughlin 1986;
Taylor 1986). Thus, an FDA staff member
(Taylor 1986) noted in 1986, when the
FDA had decided to accept the Hoechst
studies, that 
The question remains whether these studies are
sufficiently definitive or rigorous in light of the
potential for widespread, [sic] high exposure to
acesulfame K in all group [sic] in the population.
In 1996, the CSPI nominated acesul-
fame for testing in the NTP bioassay pro-
gram (CSPI 1996), and provided the NTP
with detailed information on the Hoechst
tests and their flaws. Although an individual
familiar with test design and implementa-
tion could have concluded with ease that
the Hoechst tests were not consistent with
the criteria established for NTP bioassays or
the test guidelines set out in the FDA’s
Redbook (FDA 1982), and that it was likely
that, at some point, many people would be
exposed to acesulfame, the NTP rejected
CSPI’s nomination. 
In 2003, the NTP announced the
results of tests of both aspartame and ace-
sulfame in genetically modified mice
(GMM) (NTP 2005). Both chemicals gave
negative results in the tests, carried out in
two strains of GMM. 
The NTP’s final report on those GMM
studies (NTP 2005) noted that aspartame
and acesulfame had been selected as “negative
controls” for validation tests for the GMM
models. The chemicals did indeed test nega-
tive, but that negative result did not advance
our understanding of potential carcinogenic-
ity of acesulfame. Regarding the GMM tests
of aspartame and acesulfame, Martha Sandy
of the California Environmental Protection
Agency, stated that 
[N]egative results [in the GMM tests] are not
informative as to the test substance’s carcinogenic-
ity, and point to the need to conduct standard
two-year carcinogenicity studies. At this time,
transgenic models cannot replace the two-year
bioassay and it would be unwise to list a chemical
as safe for human exposure based upon negative
results in not yet validated model systems. (Sandy
2003) 
The findings of Soffritti et al. (2006) of
multipotential carcinogenesis in rats fed
aspartame over their lifetimes provide support
for Sandy’s (2003) statements.
I have sent the NTP a new nomination
of acesulfame for 2-year bioassay testing
(Karstadt 2006). 
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Acesulfame Potassium: Soffritti
Responds
Karstadt makes an important point regard-
ing the need for more adequate long-term
carcinogenicity testing of the artificial
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her letter stimulated me to offer some addi-
tional considerations.
As reported in a previous paper (Soffritti
et al. 1999), one of the most important
issues in environmental and industrial car-
cinogenesis is how to deal with diffused car-
cinogenic risks, to which most of the planet’s
population may be exposed. These carcino-
genic risks are represented by a) agents that
are slightly carcinogenic at any dose; b) low
or extremely low doses of a carcinogenic
agent of any kind; or c) mixtures of small
doses of carcinogenic agents.
Epidemiologic and experimental studies
are fundamental in the identification and
quantification of diffused carcinogenic
risks, but they must be designed and con-
ducted to be as powerful as possible with
adequate methodology. In the case of exper-
imental studies, it is not sufficient to follow
the standard protocol used in ordinary
experiments. Instead, it is necessary to con-
duct studies that may be defined as “mega-
experiments,” using a vast number of
animals (at least 200–1,000 per experimen-
tal group) in order to express a marked dif-
ference in the variation of effects, and
exposing the animals in all phases of devel-
opment to allow the agent to express its full
carcinogenic potential. 
It is based on this rationale that the
European Ramazzini Foundation per-
formed a mega-experiment on 1,800 rats
and demonstrated that, in our experimental
conditions, aspartame is a multipotential
carcinogenic agent (Soffritti et al. 2005;
Soffritti et al. 2006).
The results of our study (Soffritti et al.
2005, 2006) attracted the attention of the sci-
entific community, consumer and industry
associations, and the national and interna-
tional agencies responsible for food safety.
Among various comments, the opinion
expressed on 5 May 2006 by the European
Food Safety Authority (EFSA 2006) and the
general interpretation of an epidemiologic
study conducted by the National Cancer
Institute (NCI 2006) necessitate comment
on our part. 
In examining the raw data of our study,
the EFSA (2006) observed a high incidence
of chronic pulmonary inflammation in males
and females in both treated groups and in
the control group. Based on this observation,
it was concluded that “the increased inci-
dence of lymphomas/leukemias reported in
treated rats was unrelated to aspartame, given
the high background incidence of chronic
inflammatory changes in the lungs.” In my
opinion, this conclusion is bizarre for the
following reasons:
First, the EFSA (2006) overlooked the
fact that the study was conducted until the
natural death of the rodents. It is well
known that infectious pathologies are part
of the natural dying process in both rodents
and humans.
Second, if the statistically significant
increased incidence of lymphomas/leukemias
observed was indeed caused by an infected
colony, one would expect to observe an
increased incidence of lymphomas/leukemias
not only in females but also in males. The
EFSA (2006) did not comment on this dis-
crepancy in their logic.
Finally, in support of the hypothesis
regarding the safety of aspartame, the EFSA
(2006) cited the negative results of recent
carcinogenicity studies carried out in trans-
genic mice by the National Toxicology
Program (NTP); the ESFA did not mention
that, because the NTP studies on geneti-
cally altered mice were performed using a
new experimental model, the NTP subcom-
mittee unanimously agreed “there is uncer-
tainty whether the study possessed sufficient
sensitivity to detect a carcinogenic effect”
(NTP 2005).
Interestingly, the same scrutiny applied
to our study has not been applied to a
recent abstract published by Lim et al.
(2006) from the NCI diet questionnaire
survey (NCI 2006) in which self-reported
aspartame consumption showed no
increases in either leukemia/lymphomas or
brain cancer. These results have been used
by industry, the EFSA, and others to argue
that aspartame is not a risk for humans, in
spite of our animal study results. Without
specific information on each individual’s
consumption rate and duration it is difficult
to assess the power of the survey, in spite of
the large number of participants. The sec-
ond related issue is whether aspartame is an
early- or late-stage carcinogen. If it is an
early-stage initiator of cancer, then report-
ing the lack of effects in older individuals
who have not consumed aspartame since
early childhood would be expected to
show little or no increased cancer (Hoel
1985).
The safety—in particular, the noncar-
cinogenicity—of today’s most widely dif-
fused artificial sweeteners and their blends is
largely based on studies conducted decades
ago. I second Karstadt’s nomination of ace-
sulfame K for further study; however, I add
that it should be evaluated using a long-
term mega-experiment. 
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Chemical Mixtures: Greater-
than-Additive Effects?
Various combinations of chemicals are
being detected in the environment with
increasing frequency. This has raised aware-
ness that we are not exposed to individual
chemicals in isolation and heightens con-
cern that the toxicity of individual chemi-
cals may not represent toxicity when the
chemicals are present in combination. Of
greatest concern is that chemicals in combi-
nation may elicit synergistic toxicity that
goes undetected in evaluations of individual
chemical toxicity.
In a recent article, Hayes et al. (2006)
assessed the effects of nine pesticides indi-
vidually (at 0.10 ppb) and in combination
(each at 0.10 ppb) on time to foreleg emer-
gence and time to complete tail resorption
in Rana pipiens. Both end points are meas-
ures of larval development in frogs. The
authors reported that the pesticide mixture
had a much greater effect on these develop-
mental parameters than did the individual
chemicals; they concluded that estimating
ecologic risk of pesticides on amphibians
using studies that examine single pesticides
may lead to gross underestimates of the role
of pesticides in amphibian declines. Clearly,
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of the nine pesticides is greater than the sum
of the individual chemicals. But is this specu-
lation of synergy warranted from these data? 
To invoke synergy, one must—at a mini-
mum—exclude the possibility of concentra-
tion or response additivity. Concentration
additivity may appear as synergy when indi-
vidual constituents, sharing the same mecha-
nism of toxicity, in a mixture are all present
below the threshold concentrations required
for toxicity. However, in combination, the
joint concentration of the constituents
exceeds that threshold concentration,
resulting in significant adversity. These
experiments were not designed to assess
concentration additivity, so no judgment can
be made either in favor of or against the pos-
sibility that the toxicity of the mixture repre-
sented concentration additivity. However,
individual responses to the nine pesticides
were shown in graph form (Figure 1; Hayes
et al. 2006), which allows for an assessment
of response additivity for the mixture. Eight
of nine pesticides prolonged the time to fore-
leg emergence, and nine of nine chemicals
prolonged the time to tail resorption.
However, these effects were not statistically
significant, with the exception of the effects
elicited by propiconzole. 
We subjected these data to analyses for
response additivity under the assumption
that the observed effects were real but were
not statistically significant due to the low
power of the experimental design. A descrip-
tion of the response additivity model is
available on our website [Computational
Approach to the Toxicity Assessment of
Mixtures (CATAM) 2006a] along with a
mixtures toxicity calculator used in these
analyses (CATAM 2006b). The response
addition model predicted that the mixture
of pesticides would prolong the time to fore-
leg emergence from 44 days to 60 days and
the time to tail resorption from 56 days to
67 days. Hayes et al. (2006) determined that
the pesticide mixture extended these devel-
opmental time points to 59 ± 2 days and
70 ± 2 days, respectively (mean ± SE; these
values are our best estimates from Hayes
et al.’s Figure 2). Thus, response addition
alone explains the toxicity associated with a
pesticide mixture. There is no need to
invoke greater-than-additive effects and no
need to raise concern that mixtures of these
pesticides cause unexpected toxicity.
Toxicity of mixtures is a perplexing
problem that warrants significant investiga-
tion. However, when assessing the toxicity
of chemical mixtures, it is prudent to test
the null hypothesis of no interactions. Only
upon rejection of this hypothesis should the
possibility of synergistic interactions be
considered. In response to the question
posed by Hayes et al. (2006) in the title of
their article—”Pesticide Mixtures … Are
We Underestimating the Impact?”—the
evidence presented suggests that the answer
is “no.”
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Chemical Mixtures: Hayes
Responds
LeBlanc and Wang point out that we did
not demonstrate synergy; they stated that “to
invoke synergy, one must—at a minimum—
exclude the possibility of concentration or
response additivity.” In fact, we did not
“invoke synergy”: in our article, not once
did we use the word “synergy.” LeBlanc and
Wang themselves “invoke synergy” simply
to show that it cannot be invoked from the
current study; their problem is with what
they inferred from our article, not with any
claims that we made. 
LeBlanc and Wang also point out that
our “experiments were not designed to assess
concentration additivity, so no judgment can
be made either in favor of or against the pos-
sibility that the toxicity of the mixture repre-
sented concentration additivity.” We agree.
This was not the aim of the study. In fact,
LeBlanc and Wang’s thesis here is merely a
restatement of our own conclusions: 
The present effects of mixtures cannot be assigned
to the categories of concentration additive or
response additive. (Hayes et al. 2006; p. 47) 
and 
The examinations needed to characterize pesticide
interactions as concentration additive or response
additive … are difficult to design and carry out and
present new challenges to regulators. Such studies
are necessary, however (Hayes et al. 2006; p. 48)
Finally, LeBlanc and Wang examined
our data for response additivity using a sim-
ple model and testing select parameters that
fit their model while ignoring others. In our
study we examined effects of nine pesticides
alone (0.1 ppb) or in three different mix-
tures at 0.1 ppb and 10 ppb on leopard frog
(Rana pipiens) larvae. Each treatment
(30 larvae/tank) was replicated three times
(1,350 larvae total). We assessed effects on
10 parameters: time to foreleg emergence
(FLE) and time to complete tail resorption
(TR), snout-vent length (SVL) and body
weight (BW) at metamorphosis, mortality,
gonadal development, thymus histology,
disease rates, and the interaction between
time to TR and SVL and BW at metamor-
phosis. Yet, according to LeBlanc and
Wang, we simply 
assessed the effects of nine pesticides individually
(at 0.10 ppb) and in combination (each at
0.10 ppb) on time to foreleg emergence and time
to complete tail resorption.
LeBlanc and Wang used their simple
model to show that the effects of one of the
pesticide mixtures on developmental time
are predictable from the nonsignificant
effects of the individual pesticides. Although
they predicted the effects of a single pesti-
cide mixture on a single variable, can their
model predict the effects of even the single
pesticides (propiconazole, λ-cyhalothrin,
and atrazine) on the interaction between
development and growth (Figure 5; Hayes
et al. 2006), when none of these compounds
significantly affected development alone and
only atrazine affected size alone? Can their
model predict the effects of atrazine plus
S-metolachlor on the relationship between
development and size or explain why the
“inert” ingredients in the commercial mix-
ture (Bicep II magnum; Syngenta Crop
Protection U.S., Research Triangle Park,
NC) appear to reduce this effect? Most cer-
tainly, the 70% meningitis infection rate in
the surviving animals exposed to the nine-
compound mixture cannot be predicted
from exposure to the single pesticides, where
disease rates were zero. The effect on devel-
opment was the only parameter that fit
LeBlanc and Wang’s model and thus
explains their reason for focusing on this sin-
gle measure and ignoring the other nine
parameters we measured.
In conclusion, the questions raised in
our article (Hayes et al. 2006) can be
answered only with empirical evidence
obtained from appropriately designed and
carefully conducted laboratory experiments,
not by simplified models that ignore inter-
actions between independent variables and
relationships between dependent variables.
Finally, and most important, our data
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ticides one at a time does not reveal the
magnitude of effects of low-dose chronic
exposure to pesticide mixtures and thus
does not allow us to accurately assess their
impacts on amphibians. Practically all of
the chemicals we examined had no signifi-
cant effects alone, but this was certainly not
the case when they were combined.
Whether or not these interactions are
response additive, concentration additive,
or synergistic is irrelevant to the real ques-
tion: Are we underestimating the impact? If
we continue to base assessments on exami-
nations of single compounds, the answer is
“yes.”
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Comparing Risk of West Nile
Virus against Risk of
Adulticiding
Peterson et al. (2006) compared the risk of
ground-based ultra-low-volume (ULV)
adulticiding against the risk of West Nile
virus (WNV). They concluded that 
[B]y virtually any current human-health measure,
the risks from infection by WNV exceed the risks
from exposure to mosquito insecticides.
Therefore, perceptions that human-health risks
from the insecticides used to control adult mos-
quitoes are greater than the risks from WNV cur-
rently cannot be supported by the current
scientific evidence.
We appreciate their elegant analysis of
health risks associated with residential expo-
sure to ground-based ULV adulticides, and
we concur that such risks are very low.
However, we are concerned that their risk–
risk comparison may be misinterpreted to
indicate that the human health risk associ-
ated with adulticiding is more than offset by
its potential for WNV disease reduction.
Peterson et al. (2006) did not provide data to
support this. Such a risk–benefit comparison
requires at least two refinements.
First, it needs to take into account inter-
vention effectiveness. Although it is not
unreasonable to expect some benefit, it is
unlikely that adulticiding is completely (or
even mostly) effective. Hence, a risk–benefit
comparison would need to address the likely
situation of adulticiding being substantially
< 100% effective, for example, by reducing
estimates of adulticiding-based benefit by a
factor of 1/x, where x represents the effec-
tiveness of adulticiding. 
Second, it needs to discount benefit based
on upstream interventions. Adulticiding
often takes place in the context of an inte-
grated mosquito/WNV management pro-
gram. In this situation, upstream approaches
(e.g., larviciding, personal protection) dis-
count the attributable benefit of down-
stream interventions (e.g., adulticiding). For
example, use of larviciding and personal
protection, respectively, providing y and z
effectiveness, reduces the potential benefit of
adulticiding by a factor of 1/[(1 – y) ×
(1 – z)].
Where upstream interventions are used
and are fairly effective and adulticiding is not
(or even if it is), adulticiding-attributable
disease reduction may by substantially less
than overall WNV risk. For example, if
larviciding is 75% effective, personal pro-
tection 90% effective, and adulticiding
10% effective, the risk reduction achieved
through adulticiding would be 1/400th of
the overall risk of WNV-related disease;
that is,
Overall risk/{1/[(x) × (1 – y) × (1 – z)]}.
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West Nile Virus: Peterson et al.
Respond
We thank Schofield et al. for their interest
in our article and for their comments. We
would like to clarify that Peterson et al.
(2006) is simply a screening-level (tier 1)
risk assessment in which we separately and
conservatively examined the residential
human risks from exposure to West Nile
virus (WNV) and mosquito adulticides. As
with all screening-level risk assessments,
our assessments were not refined, but they
did reveal the magnitude of risk compared
to relevant end points. As Schofield et al.
point out, our article should not be mis-
interpreted to indicate that the health risks
associated with adulticiding are offset by
its potential for WNV reduction. This is
because we did not conduct a risk–benefit
assessment, which was beyond the scope of
our study. 
Our article (Peterson et al. 2006) repre-
sents an initial step in an ongoing multiyear
analysis of risk issues associated with certain
vectorborne diseases and vector manage-
ment strategies. We plan to address some of
the issues Schofield et al. raise in subsequent
papers. 
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